 |
|
|
|
|
| Important Product Safety Information |
| |
Kepivance® is indicated to decrease the incidence and duration of
severe oral mucositis in patients with hematologic malignancies
receiving myelotoxic therapy requiring hematopoietic stem cell
support. The safety and efficacy of Kepivance® have not been
established in patients with non-hematologic malignancies.
In patients with hematologic malignancies, the most common serious adverse reaction in clinical trials attributed to Kepivance®
was skin rash reported in less than 1% of patients. Other serious adverse reactions occurred at a similar rate in patients who received
Kepivance® or placebo with the most frequent being fever, gastrointestinal events, and respiratory events.
The most commonly reported adverse reactions attributed to Kepivance® were rash, erythema, edema, pruritus, dysesthesia,
mouth/tongue thickness/discoloration, and taste alteration.
View full Kepivance® product information page.
ABOUT ORAL MUCOSITIS
ABOUT KEPIVANCE®
TOOLS AND RESOURCES
FOR NURSES
FOR PHARMACISTS
IMPORTANT PRODUCT SAFETY INFORMATION
|
 |
|
| |
|
|
|
|
|
